185 results on '"Damiani, Arianna"'
Search Results
2. Brain-Computer Interface to Deliver Individualized Multisensory Intervention for Neuropathic Pain
3. Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level
4. JAK inhibitors and autoimmune rheumatic diseases
5. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
6. Thalamic stereoelectroencephalography for neuromodulation target selection: Proof of concept and review of literature of pulvinar direct electrical stimulation
7. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
8. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
9. Can Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for Pulmonary Arterial Hypertension? Description of a Real-Life Case Series.
10. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65).
11. May Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for PAH? Description of a Real-Life Case Series
12. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab
13. GABA Increases Sensory Transmission In Monkeys
14. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA- i Study).
15. ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
16. Targeted Deep Brain Stimulation of the Motor Thalamus Facilitates Voluntary Motor Control After Cortico-spinal Tract Lesions
17. TARGETED DEEP BRAIN STIMULATION OF THE MOTOR THALAMUS FACILITATES VOLUNTARY MOTOR CONTROL AFTER CORTICO-SPINAL TRACT LESIONS
18. Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study
19. Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174
20. A systematic review of computational models for the design of spinal cord stimulation therapies: from neural circuits to patient‐specific simulations.
21. A systematic review of computational models for the design of spinal cord stimulation therapies: from neural circuits to patient‐specific simulations
22. The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
23. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
24. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
25. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
26. A Computational Study of Lower Urinary Tract Nerve Recruitment with Epidural Stimulation of the Lumbosacral Spinal Cord
27. Comparison of ultrasound attenuation by calcium pyrophosphate, hydroxyapatite and monosodium urate crystals: a proof-of-concept study
28. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?
29. Persistence of remission after lengthening of golimumab in inflammatory joint diseases
30. Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
31. Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements
32. Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response”by Bonelli et al
33. Do new and old biomarkers of early undifferentiated arthritis correlate with Arthritis Impact Measurement Scales?
34. Closing the serological gap in the diagnostic testing for COVID‐19: The value of anti‐SARS‐CoV‐2 IgA antibodies
35. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koopset al
36. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD
37. COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients
38. Vantaggi, limiti e prospettive dei test sierologici nell'infezione da SARS-CoV-2 (COVID-19)
39. Old and new antirheumatic drugs for the treatment of COVID-19
40. Médicaments rhumatologiques pour le traitement de l’infection par le COVID-19
41. Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity
42. Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
43. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports
44. Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements
45. Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
46. DYRK1B INHIBITORS ARE SYNERGISTIC WITH CYTOTOXICS DYRK1B IHC STAINING OF THE PATIENT OVARIAN TUMORS Table 2. DYRK1B IHC STAINING in OVARIAN CARCINOMA FFPR TUMOR TISSUES and CONTROL OVARIAN TISSUES: POSITIVY and INTENSITY
47. Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2–Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays
48. Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience
49. The Laboratory Role in anti-TNF Biological Therapy Era
50. Abstract 3038: Implication of DYRK1B Kinase in ovarian cancers and utilization of DYRK1B Inhibitors as a novel therapeutic strategy for ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.